Welcome to the ATOMIC2 trial website! This study is now closed to recruitment. Please see the Results tab for further information.
Full study title: A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19....
PURPOSE OF THE TRIAL
The purpose of this study is to assess whether the use of a commonly given antibiotic called Azithromycin can prevent or makes no difference to patients getting worse, otherwise known as disease progression of Novel Coronavirus-Induced Disease 2019 (COVID-19) in people who go to hospital, but who doctors decide there is no need to admit them for treatment.
We have been funded by various charities and funding bodies to find out whether taking Azithromycin for 14 days makes any difference to the number of people who go on to develop more severe symptoms of COVID-19. We will do this by half of those taking part in the study having standard NHS care, and half of those taking part in the study having standard NHS care and being given 14 days of Azithromycin tablets to take. We will then assess, after 28 days, whether there are less people in either of the groups who develop a more severe infection. This study will allow a definite answer to be found, so that doctors know if giving patients Azithromycin when they come to hospital with COVID-19 symptoms makes any difference to the disease getting worse or not.
Please note that recruitment to this trial has now closed. Thank you to everyone involved!!
We are hoping to enrol up to 800 men and women aged 18 or over from at least 4 NHS hospitals in the UK to our ATOMIC2 study.
To find out what would be involved if you chose to take part, including the potential benefits and risks, click here.
Azithromycin is an antibiotic which is widely and safely used to treat infections and excessive inflammation in the lung, for conditions such as pneumonia, and infections of the nose and throat such as sinus infection (sinusitis). It is also often used in children to treat chest and ear infections. It is a type of antibiotic that fights infection by killing bacteria, and it also has properties that fight viral infections and reduces inflammation. These additional anti-viral properties have led to its use in other viral infections similar to COVID-19 but it is yet to be known if it will help patients with COVID-19.
Friday 9th July 2021
Full results of the now published in The Lancet – click to see ATOMIC2 results
Friday 23rd April 2021
ATOMIC results press release now available – click to see ATOMIC2 results
Monday 1st February 2021
Trial recruitment paused.
Tuesday 20th October 2020
Darlington Memorial Hospital opens to recruitment!
Tuesday 6th October 2020
Two more sites open to recruitment!
- University Hospital of North Tees
- University College Hospital London
Monday 21st September 2020
St George's University Hospital opens to recruitment!
Monday 7th September 2020
James Cook University Hospital now open for recruitment!
Thursday 30th July 2020
Two more sites open to recruitment!
- King's College Hospital - Denmark Hill
- Princess Royal University Hospital
Thursday 16th July 2020
Royal London Hospital site opens to recruitment!
Tuesday 30th June 2020
Two more sites open to recruitment!
- Royal Berkshire Hospital
- Royal Derby Hospital
Tuesday 16th June 2020
Basingstoke & North Hampshire Hospital opens to recruitment!
Friday 5th June 2020
Three more sites open to recruitment!
- Royal Blackburn Teaching Hospital
- University Hospital of Llandough
- University Hospital of Wales
Wednesday 3rd June 2020
John Radcliffe Hospital recruits ATOMIC2's first participant!
Friday 29th May 2020
Two more sites open to recruitment!
- John Radcliffe Hospital
- Horton General Hospital
Thursday 28th May 2020
First three sites open to recruitment!
- Birmingham City Hospital
- Sandwell Hospital
- Ninewells Hospital
Wednesday 6th May 2020
First Trial DSMC and TSC meeting held remotely.
Tuesday 5th May 2020
Trial received REC approval.
Friday 1st May 2020
Trial received MHRA approval.
Monday 20th April 2020
The ATOMIC2 trial is currently in set-up and the team hope to open to recruitment soon!
